Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels
Autore:
Maclaine, GDH; Patel, H;
Indirizzi:
Pfizer Ltd, Dept Med, Sandwich CT13 9NJ, Kent, England Pfizer Ltd Sandwich Kent England CT13 9NJ andwich CT13 9NJ, Kent, England
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 4, volume: 55, anno: 2001,
pagine: 243 - 249
SICI:
1368-5031(200105)55:4<243:ACMOAS>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; EFFICACY; ATORVASTATIN; SIMVASTATIN; FLUVASTATIN; PREVENTION; BENEFIT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Maclaine, GDH Pfizer Ltd, Dept Med, Ramsgate Rd, Sandwich CT13 9NJ, Kent, England Pfizer Ltd Ramsgate Rd Sandwich Kent England CT13 9NJ ngland
Citazione:
G.D.H. Maclaine e H. Patel, "A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels", INT J CL PR, 55(4), 2001, pp. 243-249

Abstract

An economic model was developed to estimate the relative cost-effectiveness of alternative HMG-CoA reductase inhibitors (statins)-atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin - to achieve target low-density lipoprotein cholesterol (LDL-C) levels in a population of secondary CHD prevention patients. By using a cholesterol target as the endpoint of interest and a dose titration approach, the model assumes that the statins demonstrate a class effect through cholesterol lowering. The model was used to estimate the proportion of patients achieving target LDL-C levels (<3 mmol/l) under each scenario tested. Total costs and incremental cost-effectiveness relative to no treatment and to the lowest cost option were estimatedfor each scenario. Total costs were highest for pravastatin and lowest forcerivastatin, Compared with no treatment, the incremental cost per patienttreated to target LDL-C varied between pound 383 (atorvastatin) and pound 1213 (pravastatin). Incremental cost-effectiveness ratios in comparison with the lowest cost treatment (cerivastatin) were pound 141 per additional patient achieving target LDL-C with atorvastatin, and pound 275 with simvastatin, Fluvastatin and pravastatin were both less effective and more expensive than the lowest cost therapy. Although cerivastatin was associated with lowest expected costs, therapy with atorvastatin achieved the lowest cost-effectiveness ratios. Hence atorvastatin would allow the largest number of patients to be treated to target LDL-C within a fixed drug budget. Choosing between drug therapies on the basis of price alone may be misleading if the effectiveness of therapies varies.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/04/20 alle ore 22:32:00